All In Biotech

Drug Trial Radar · NCT03980054

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

A Phase III Study to Evaluate the Efficacy and Safety of Pyrotinib Versus Placebo in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,135 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,135

Actual

Start

Jul 12, 2019

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Jun 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy and safety of pyrotinib in women with early stage high-risk breast cancer after adjuvant trastuzumab. The main purpose of this study is to investigate whether pyrotinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.

Conditions

  • Breast Cancer

Interventions

  • PyrotinibDrug

    pyrotinib 400 mg, orally once daily for one year

  • PlaceboDrug

    placebo 400mg, orally once daily for one year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-free Survival (iDFS)Time frame: From randomization until time of event up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Cancer Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.